Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-05-29
1997-02-11
Weimar, Elizabeth C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
562575, 562445, A61K 3805
Patent
active
056021020
ABSTRACT:
Therapeutic agents and methods for the treatment of immunologically mediated diseases and malignancies of myeloid cell or lymphoid cell origin. These particular methods utilize the characterization of particular activation mechanisms important to the progression of these pathologies in humans. Selective inhibition of cell types responsible for precipitating these disorders in humans are provided with therapeutic agents which include peptides capable of inhibiting dipeptidyl peptidase-I activation of proenzymes present primarily in cytotoxic T-cells and myeloid cells, such as Gly--Phe--CHN.sub.2. Antisense oligonucleotides are also characterized which are specific for human dipeptidyl peptidase-I gene which may be used in the treatment of the described disorders.
REFERENCES:
patent: 4752602 (1988-06-01), Lipsky et al.
patent: 5047401 (1991-09-01), Lipsky et al.
patent: 5068223 (1991-11-01), Lipsky et al.
patent: 5223486 (1993-06-01), Gordon
patent: 5403919 (1995-04-01), Butcher
Thiele, D. L., and P. E. Lipsky (1990), The action of leucyl-leucine methyl ester on cytotoxic lymphocytes requires uptake by a novel dipeptide-specific facilitated transport system and dipeptidyl peptidase I-mediated conversion to membranolytic products, J. Exp. Med., 172:183-194, published in USA.
Salvesen, G., and J. J. Enghild (1990), An unusual specificity in the activation of neutrophil serine proteinase zymogens, Biochemistry, 29:5304, published in USA.
Vanderslice, P., C. S. Craik, J. A. Nadel, and G. H. Caughey (1989), Molecular cloning of dog mast cell tryptase and a related protease: structural evidence of a unique mode of serine protease activation, Biochemistry, 28:4148, published in USA.
Reynolds, D. S., R. L. Stevens, W. S. Lane, M. H. Carr, K. F. Austen, and W. Serafin (1990), Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases, Proc. Natl. Acad. Sci., USA 87:3230, published in USA.
Shaw, E., and G. D. J. Green (1981), Inactivation of thiol proteases with peptidyl diazomethyl ketones in Methods in Enzymology edited by S. P. Colowick and L. Lorand, 80:820, Academic Press, New York, published in USA.
Green, G. D. J., and E. Shaw (1981), Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases, J. Biol. Chem., 256:1923, published in USA.
Shaw, E. (1990) Cysteinyl proteinases and their selective inactivation in Advances in enzymology and related areas of molecular biology edited by A. Meister, 63:271, Interscience Publications, J. Wiley and Sons, New York, published in USA.
McDonald, J. K., P. X. Callahan, B. B. Zeitman, and S. Ellis (1969) Inactivation and degradation of glucagon by dipeptidyl aminopeptidase I (cathepsin C) of rat liver including a comparative study of secretin degradation, J. Biol. Chem., 244:6199, published in USA.
Raff, R. F., E. Severns, R. Storb, P. Martin, T. Graham, B. Sandmaier, F. Schuening, G. Sale, and F. R. Appelbaum (1988), L-Leucyl-l-leucine methyl ester treatment of canine marrow and peripheral blood cells, Transplantation, 46:655, published in USA.
McDonald, J. K., B. B. Zeitman, T. J. Reilly, and S. Ellis (1969), New observations on the substrate specificity of cathepsin C (dipeptidyl aminopeptidase I), J. Biol. Chem., 244:2693, published in USA.
Thiele, D. L., Charley, M. R., Calomeni, J. A. and Lipsky, P. E., Lethal graft-vs-host disease across major histocompatibility barriers: Requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells, J. Immunol 138:51-57, 1987, published in USA.
Thiele, S. L., Calomeni, J. A. and Lipsky, P. E., Leucyl-Leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent.fwdarw.F1 chimeras that are selectively tolerant of host alloantigens, J. Immunol., 139:2137-2137-2142, 1987, published in USA.
Blazar, B. R., Thiel, D. L. and Vallera, D. A., Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: Elimination of graft-versus-host disease without detrimental effects on engraftment, Blood, 75:798-805, 1990, published in USA.
McGuire, M. J., Lipsky, P. E., and Thiele, D. L., Purification and characterization of human dipeptidyl peptidase I (DPPI). FASEB J, 5:A827, 1991, published in Europe.
Thiele, D. L. and Lipsky, P. E., Apoptosis is an essential step in leucyl-leucine methyl ester (Leu-Leu-OMe) mediated killing of cytotoxic lymphocytes and myeloid cells, FASEB J, 5:A973, 1991, published in Europe.
Thompson, S. A., P. R. Andrews, and R. P. Hanzlik (1986), Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29:104-111, published in USA.
Thiele, D. L. and P. E. Lipsky (1985), Modulation of Human natural killer cell function by L-leucine methyl ester: monocyte-dependent depletion from human peripheral blood mononuclear cells, J. Immunol., 134:786-793, published in USA.
Senior, R. M., E. J. Campbell, (1984), Cathepsin G in human mononuclear phagocytes: comparisons between monocytes and U937 moncyte-like cells, J. Immunol., 132:2547-2551, published in USA.
Angliker, H., P. Wikstrom, H. Kirschke and E. Shaw (1989), The inactivation of the cysteinyl exopeptidases cathepsin H and C by affinity-labelling reagents, Biochem. J., 262:63-68, published in Great Britain.
Lathe, R., (1985), Synthetic oligonucleotide probes deduced from amino acid sequence data theoretical and practical considerations, J. Mol. Biol., 183:1-12, published in Europe.
Ishidoh, K. D. Muno, N. Sato and E. Kominami (1991), Molecular Cloning of cDNA for rat cathepsin D, J. Biol. chem., 256(25):16312-16317, Sep. 5, 1991, published in USA.
Enzyme System Products, 6497 Sierra Lane, Dublin, CA 9468, published in USA.
McGuire, Michael J., Lipsky, Peter E., and Thiele, Dwain L., Purification and characterization of dipeptidyl peptidase I.sup.1 from human spleen, Archives of Biochem. Biophys., 295(2):001-009, 1992, published in USA.
Dialog searches produced in USA.
McGuire et al., "Purification and Characterization of Human Dipeptidyl Peptidase I (DPPI)," The Faseb Journal, Part I: Abstracts of the 75th Annual Meeting, Atlanta, Georgia, Apr. 21-25, 1991, Abstract No. 2655.
Thiele and Lipsky, "Mechanism of L-Leucyl-L-Leucine Methyl Ester-Mediated Killing of Cytotoxic Lymphocytes: Dependence on a Lysosomal Thiol Protease, Dipeptidyl Peptidase I, That is Enriched in These Cells," Proc. Natl. Acad. Sci. USA, 87(1):83-87, 1990.
Falanga et al., "Inhibition of Cancer Procoagulant by Peptidyl Diazomethyl Ketones and Peptidyl Sulfonium Salts," Thrombosis Research, 54:389-398, 1989.
Green and Shaw, "Peptidyl Diazomethyl Ketones Are Specific Inactivators of Thiol Proteinases," J. Biol. chem., 256(4):1923-1928, 1981.
Imperiali and Abeles, "Inhibition of Serine Proteases by Peptidyl Fluoromethyl Ketones," Biochemistry, 25:3760-3767, 1986.
Ishidoh et al., "Molecular Cloning of cDNA for Rat Cathepsin C," J. Biol. Chem., 266(25):16312-16317, 1991.
McGuire et al., "Purification and Characterization of Dipeptidyl Peptidase I from Human Spleen," Arch. Biochem. Biophys., 295(2):280-288, 1992.
McGuire et al., "Generation of Active Myeloid and Lymphoid Granule Serine Proteases Requires Processing by the Granule Thiol Protease Dipeptidyl Peptidase I," J. Biol. Chem., 268(4):2458-2467, 1993.
Randell Inflammation 12, 67, 1988.
Crawford Biochem J 253, 751, 1988.
Lipsky Peter E.
McGuire Michael J.
Thiele Dwain L.
Board of Regents, The Univ. of TX System
Lukton David
Mayfield Denise L.
Weimar Elizabeth C.
LandOfFree
Dipeptidyl peptidase-I inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipeptidyl peptidase-I inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipeptidyl peptidase-I inhibitors and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342028